Uricaemia and associated health determinants in a paediatric population in Mexico

Lares-Villaseñor, E.; Salazar-García, Samuel; Cossío-Torres, Patricia Elizabeth; Aradillas‐García, Celia; Portales-Pérez, Diana Patricia; Vargas-Morales, Juan Manuel

doi:10.1016/j.numecd.2022.02.010

Cited by 2 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 However, nutritional and biochemical serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. 6,10,12 In previous studies, hyperuricemia has been independently associated with a higher risk of hypertension, hyperlipidemia, clinical disease activity, organ damage, and pulmonary arterial pressure in SLE patients. [13][14][15][16] Notably, hyperuricemia has been described as an independent risk factor for kidney damage and lupus nephritis (LN) in SLE, and it may be considered a good predictor for kidney injury.…”

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

“…9 However, nutritional and biochemical serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. 6,10,12…”

Section: Introductionmentioning

confidence: 99%

“…5 In the general population, cardiometabolic health determinants that define the CVD risk such as metabolic syndrome (MetS), excess weight, dyslipidemia, and unhealthy nutritional status have been associated with about the 80% of premature deaths worldwide. 6 In SLE patients, alterations in these cardiometabolic health determinants as well as pharmacotherapy side effects, could favor in a synergistic way a worse clinical disease activity, organ damage, and mortality. 7,8 Uric acid, a metabolite produced mainly in the liver, is the end-product of human dietary and endogenous purine metabolism.…”

Section: Introductionmentioning

confidence: 99%

“…Currently, it is described as a novel cardiometabolic biomarker associated with CVD outcomes such as MetS, hypertension, coronary atherosclerotic heart disease, atrial fibrillation, heart failure, and chronic renal diseases in the general population. 6,9,10 The uric acid serum levels greater than 6 mg/dL for women and 7 mg/dL for men are defined as hyperuricemia. 9,11 One of the mechanisms that induce hyperuricemia is the release and degradation of purines derived from nucleic acids due to necrosis; also, the released autoantigens would induce the activation of inflammatory pathways.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients: Relationship with clinical and renal disease activity

Campos-López

Meza-Meza

Pesqueda-Cendejas

et al. 2022

Lupus

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is the prototypical autoimmune disease considered as an independent risk factor for mortality by cardiovascular disease. Currently, uric acid is described as a novel biomarker associated with cardiometabolic risk. However, nutritional and serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. This study aimed to assess the nutritional, biochemical, and cardiometabolic determinants of hyperuricemia and its relationship with clinical variables in SLE patients. A cross-sectional study was conducted in 167 SLE patients and 195 control subjects (CS). Nutrient intake, anthropometry, biochemical, and cardiometabolic indexes were evaluated. In SLE patients, adequate protein (OR = 0.4; p = 0.04) and carbohydrate (OR = 0.2; p = 0.01) intakes were associated with a lower risk of hyperuricemia. SLE patients with hyperuricemia presented a higher risk of clinical (OR = 2.2; p = 0.03) and renal activity (OR = 3.4; p < 0.01), as well as triglycerides ≥150 mg/dL (OR = 3.6; p < 0.01), hs-CRP ≥1 mg/L (OR = 3.1; p < 0.01), Kannel score ≥3 (OR = 2.5; p = 0.02), and BMI ≥25 kg/m2 (OR = 2.2; p = 0.02). Oppositely, serum levels of HDL-C ≥40 mg/dL (OR = 0.2; p < 0.01) were associated with a lower risk of hyperuricemia. According to the pharmacotherapy administered, prednisone treatment was associated with a high risk of hyperuricemia (OR = 4.7; p < 0.001). In contrast, the hydroxychloroquine treatment was associated with a lower risk of hyperuricemia (OR = 0.4; p = 0.02). In conclusion, SLE patients with hyperuricemia presented a high risk of clinical and renal activity as well as worse cardiometabolic status. Notably, an adequate intake of protein, carbohydrates, healthy HDL-C serum levels, and hydroxychloroquine treatment could be determinants of lower risk of hyperuricemia.

show abstract

Section: Introductionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

“…9 However, nutritional and biochemical serum determinants that influence hyperuricemia development in autoimmune diseases have not been fully elucidated. 6,10,12…”

Section: Introductionmentioning

confidence: 99%